a:5:{s:8:"template";s:9184:"<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8"/>
<meta content="text/html; charset=utf-8" http-equiv="content-type"/>
<meta content="IE=edge" http-equiv="X-UA-Compatible"/>
<meta content="width=device-width, initial-scale=1" name="viewport"/>
<title>{{ keyword }}</title>
<link href="https://fonts.googleapis.com/css?family=Roboto+Condensed%3A300%2C300i%2C400%2C400i%2C600%2C600i%2C800%2C800i&amp;subset=latin%2Clatin-ext" id="bulk-fonts-css" media="all" rel="stylesheet" type="text/css"/>
<style rel="stylesheet" type="text/css">@supports ((position:-webkit-sticky) or (position:sticky)){}@supports ((position:-webkit-sticky) or (position:sticky)){}@supports ((position:-webkit-sticky) or (position:sticky)){}p.has-drop-cap:not(:focus)::first-letter{float:left;font-size:8.4em;line-height:.68;font-weight:100;margin:.05em .1em 0 0;text-transform:uppercase;font-style:normal}p.has-drop-cap:not(:focus)::after{content:"";display:table;clear:both;padding-top:14px} @font-face{font-family:'Roboto Condensed';font-style:italic;font-weight:300;src:local('Roboto Condensed Light Italic'),local('RobotoCondensed-LightItalic'),url(https://fonts.gstatic.com/s/robotocondensed/v18/ieVg2ZhZI2eCN5jzbjEETS9weq8-19eDpCEoY9Nc.ttf) format('truetype')}@font-face{font-family:'Roboto Condensed';font-style:italic;font-weight:400;src:local('Roboto Condensed Italic'),local('RobotoCondensed-Italic'),url(https://fonts.gstatic.com/s/robotocondensed/v18/ieVj2ZhZI2eCN5jzbjEETS9weq8-19eLAQM4.ttf) format('truetype')}@font-face{font-family:'Roboto Condensed';font-style:normal;font-weight:300;src:local('Roboto Condensed Light'),local('RobotoCondensed-Light'),url(https://fonts.gstatic.com/s/robotocondensed/v18/ieVi2ZhZI2eCN5jzbjEETS9weq8-33mZGCoYag.ttf) format('truetype')}@font-face{font-family:'Roboto Condensed';font-style:normal;font-weight:400;src:local('Roboto Condensed'),local('RobotoCondensed-Regular'),url(https://fonts.gstatic.com/s/robotocondensed/v18/ieVl2ZhZI2eCN5jzbjEETS9weq8-19y7CA.ttf) format('truetype')} /*! normalize.css v3.0.3 | MIT License | github.com/necolas/normalize.css */html{font-family:sans-serif;-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%}body{margin:0}footer,nav{display:block}a{background-color:transparent}a:active,a:hover{outline:0}*{-webkit-box-sizing:border-box;-moz-box-sizing:border-box;box-sizing:border-box}:after,:before{-webkit-box-sizing:border-box;-moz-box-sizing:border-box;box-sizing:border-box}html{font-size:10px;-webkit-tap-highlight-color:transparent}body{font-family:"Helvetica Neue",Helvetica,Arial,sans-serif;font-size:14px;line-height:1.42857143;color:#333;background-color:#fff}a{color:#337ab7;text-decoration:none}a:focus,a:hover{color:#23527c;text-decoration:underline}a:focus{outline:5px auto -webkit-focus-ring-color;outline-offset:-2px}p{margin:0 0 10px}.text-center{text-align:center}ul{margin-top:0;margin-bottom:10px}.container{margin-right:auto;margin-left:auto;padding-left:15px;padding-right:15px}@media (min-width:768px){.container{width:750px}}@media (min-width:992px){.container{width:970px}}@media (min-width:1200px){.container{width:1170px}}.container-fluid{margin-right:auto;margin-left:auto;padding-left:15px;padding-right:15px}.row{margin-left:-15px;margin-right:-15px}.dropdown{position:relative}.dropdown-toggle:focus{outline:0}.nav{margin-bottom:0;padding-left:0;list-style:none}.nav>li{position:relative;display:block}.nav>li>a{position:relative;display:block;padding:10px 15px}.nav>li>a:focus,.nav>li>a:hover{text-decoration:none;background-color:#eee}.navbar{position:relative;min-height:50px;margin-bottom:20px;border:1px solid transparent}@media (min-width:768px){.navbar{border-radius:4px}}@media (min-width:768px){.navbar-header{float:left}}.container>.navbar-header{margin-right:-15px;margin-left:-15px}@media (min-width:768px){.container>.navbar-header{margin-right:0;margin-left:0}}.navbar-fixed-top{position:fixed;right:0;left:0;z-index:1030}@media (min-width:768px){.navbar-fixed-top{border-radius:0}}.navbar-fixed-top{top:0;border-width:0 0 1px}.navbar-brand{float:left;padding:15px 15px;font-size:18px;line-height:20px;height:50px}.navbar-brand:focus,.navbar-brand:hover{text-decoration:none}@media (min-width:768px){.navbar>.container .navbar-brand{margin-left:-15px}}.navbar-nav{margin:7.5px -15px}.navbar-nav>li>a{padding-top:10px;padding-bottom:10px;line-height:20px}@media (min-width:768px){.navbar-nav{float:left;margin:0}.navbar-nav>li{float:left}.navbar-nav>li>a{padding-top:15px;padding-bottom:15px}}@media (min-width:768px){.navbar-right{float:right!important;margin-right:-15px}}.navbar-default{background-color:#f8f8f8;border-color:#e7e7e7}.navbar-default .navbar-brand{color:#777}.navbar-default .navbar-brand:focus,.navbar-default .navbar-brand:hover{color:#5e5e5e;background-color:transparent}.navbar-default .navbar-nav>li>a{color:#777}.navbar-default .navbar-nav>li>a:focus,.navbar-default .navbar-nav>li>a:hover{color:#333;background-color:transparent}.container-fluid:after,.container-fluid:before,.container:after,.container:before,.nav:after,.nav:before,.navbar-header:after,.navbar-header:before,.navbar:after,.navbar:before,.row:after,.row:before{content:" ";display:table}.container-fluid:after,.container:after,.nav:after,.navbar-header:after,.navbar:after,.row:after{clear:both}@-ms-viewport{width:device-width}body,html{overflow-x:hidden}body{font-family:'Roboto Condensed',"Helvetica Neue",helvetica,arial,sans-serif;padding:0;color:#404040;font-weight:400;line-height:1.8;font-size:16px;word-wrap:break-word;overflow-x:hidden}a,a:active,a:focus,a:hover{text-decoration:none;color:#0090ff}ul{padding-left:20px}a:active{border-bottom:none}.page-area{padding-top:70px}@media (min-width:768px){.navbar-nav>li>a{padding-top:25px;padding-bottom:25px;transition:all .5s ease-in-out;-moz-transition:all .5s ease-in-out;-webkit-transition:all .5s ease-in-out;-o-transition:all .5s ease-in-out}#site-navigation .container{padding-left:0;padding-right:0}}@media (max-width:767px){.navbar-nav a:focus,.navbar-nav a:hover{color:#fff!important;background-color:#000!important}.menu-container{width:70%;position:absolute;left:0;height:100vh;transform:translate3d(-100%,0,0);overflow-y:auto;overflow-x:auto;background-color:#fff;top:100%}.navbar-brand{padding-right:55px!important}.page-area{left:0;transform:translate3d(0,0,0);transition:transform .5s ease}.navbar-nav{padding:0;margin:0}.navbar-nav a{font-size:14px;padding:12px 10px!important;margin:0!important;line-height:16px!important;float:left!important;margin:0!important;width:100%;text-transform:none!important;word-wrap:break-word;white-space:normal!important}.navbar-nav li{padding:0!important;margin:0!important}}#site-navigation{min-height:70px}.navbar-nav>li>a{border-bottom:0;text-transform:uppercase}.site-title{margin:0;padding:0;font-size:22px;line-height:28px}p.site-description{font-size:13px;line-height:18px;margin:0;-webkit-transition:all .5s ease;transition:all .5s ease}.site-branding-logo{float:left}.site-branding-logo a{border:none;z-index:9999;position:relative}.navbar-brand{padding:10px 15px;height:auto;z-index:99999;position:relative;z-index:1}.navbar{margin-bottom:0}.main-menu{position:relative}.navbar-fixed-top{position:absolute}#site-navigation{background-color:#fff;-webkit-box-shadow:0 10px 20px -12px rgba(0,0,0,.42),0 3px 20px 0 rgba(0,0,0,.12),0 8px 10px -5px rgba(0,0,0,.2);box-shadow:0 10px 20px -12px rgba(0,0,0,.42),0 3px 20px 0 rgba(0,0,0,.12),0 8px 10px -5px rgba(0,0,0,.2);border:none}#site-navigation,nav a{-webkit-transition:all .3s ease;transition:all .3s ease;color:#000}.footer-credits{border-top:1px solid #ccc;padding:15px;clear:both;margin-top:20px;background-color:#fff}</style>
 </head>
<body class="wp-custom-logo" id="blog">
<div class="main-menu">
<nav class="navbar navbar-default navbar-fixed-top" id="site-navigation">
<div class="container">
<div class="navbar-header">
<div class="site-header">
<div class="site-branding-logo">
<a class="custom-logo-link" href="#" itemprop="url" rel="home"></a> </div>
<div class="site-branding-text navbar-brand">
<p class="site-title"><a href="#" rel="home">{{ keyword }}</a></p>
<p class="site-description">
{{ keyword }}</p>
</div>
</div>
</div>
<div class="menu-container"><ul class="nav navbar-nav navbar-right" id="menu-menu-1"><li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-72 dropdown" id="menu-item-72"><a class="dropdown-toggle" data-toggle="dropdown" href="#" title="Projects">Projects</a>
</li>
<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-73 dropdown" id="menu-item-73"><a class="dropdown-toggle" data-toggle="dropdown" href="#" title="About">About</a>
</li>
<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-74" id="menu-item-74"><a href="#" title="Contacts">Contacts</a></li>
</ul></div> </div>
</nav>
</div>
<div class="page-area">	
{{ text }}
<br>
<br>
{{ links }}
</div>
<footer class="footer-credits container-fluid row" id="colophon">
<div class="container">
<p class="footer-credits-text text-center">{{ keyword }} 2020</p>
</div>
</footer>
</body>
</html>";s:4:"text";s:11099:"In May 2002, Guidant was the first company to receive approval in the United States to market cardiac resynchronization therapy defibrillators (CRT-D). Members of Guidant''s Management Committee and the Japanese Advisory Board, which is composed of senior Japanese advisors drawn from government and business, gathered in Tokyo today to celebrate the opening of the Institute. Sorry, online product manuals are not available for your country. The company, driven by a strong entrepreneurial culture of 11,000 employees, develops, manufactures and markets a broad array of products and services that enable less invasive care for some of life''s most threatening medical conditions. Boston Scientific does not provide electronic product literature for all countries and/or products. These features offer clinicians additional programming options, both during and post implant. ©2019 Boston Scientific Corporation or its affiliates. Boston Scientific is dedicated to transforming lives through innovative medical solutions that improve the health of patients around the world. Guidant continually works with government agencies, elected officials, physicians and patient advocacy groups to help ensure timely access to new technologies for the patients who will benefit from these medical innovations. Consequently, the chambers do not fill and empty normally, so the heart's pumping efficiency is compromised. Cardiac Resynchronization Therapy (CRT) Devices, Medical Device ID Cards - Pacemaker, ICD, & CRT devices, Remote Patient Monitoring and Diagnostic Monitoring - Boston Scientific. The first implant of the EASYTRAK 3/RENEWAL 3 system occurred at the University of Massachusetts Medical Center and was performed by Dr. Larry Rosenthal. Guidant Corporation by Boston Scientific Corporation are the largest market shareholders in several coronary medical device markets in the U.S., together accounting for 90% of the U.S. PTCA balloon catheter market and 85% of the U.S. coronary guidewire market. As a leader in technical innovation, Guidant is providing heart failure patients and the physicians who treat them with device-based solutions designed to extend and improve life. The group addressed several members of the Japanese media on site to tour the Institute. Explore Educare, our globally recognized education program, Fueling the next generation of life science professionals. Guidant's Institute for Therapy Advancement - Japan Continues Leadership in Medical Education Boston Scientific does not provide electronic product literature for all countries and/or products. Some device and browser combinations may not display well. Guidant is advancing clinical science by sponsoring landmark studies such as the Comparison of Medical Therapy, Pacing, and Defibrillation in Chronic Heart Failure (COMPANION) trial. and Tokyo, Japan - Guidant Corporation (NYSE: GDT), a world leader in the treatment of cardiac and vascular disease, today announced the establishment of the Guidant Institute for Therapy Advancement - Japan, an innovative facility in Tokyo that will provide physicians with unique opportunities to enhance their knowledge and expertise on the most current cardiovascular therapies and techniques. The new facility will begin offering programs in the third quarter of 2003. Under that agreement, Boston Scientific will acquire all the outstanding shares of Guidant for a combination of cash and stock worth $80 per Guidant share, or approximately $27 billion in aggregate. Along the way we have invested more than $350 million to provide heart failure patients and the physicians who treat them with innovative, effective therapies to battle this debilitating condition." Guidant Corporation pioneers lifesaving technology, giving an opportunity for better life today to millions of cardiac and vascular patients worldwide. Review literature before using or implanting a device, or performing follow-up care. Nearly one million new cases of heart failure are diagnosed annually worldwide, making it the most rapidly growing cardiovascular disorder. The U.S. trial is designed to determine the safety and efficacy of the EASYTRAK® 3 lead''s new features, including the lead''s unique spiral shape. "The EASYTRAK 3 trial is another example of Guidant''s commitment to research, development and clinical science designed to advance new treatment options for patients who struggle with heart failure," said Fred McCoy, president, Cardiac Rhythm Management, Guidant Corporation. Explore Educare, our globally recognized education program, Fueling the next generation of life science professionals.  Guidant Corporation pioneers lifesaving technology, giving an opportunity for better life today to millions of cardiac and vascular patients worldwide. "This system offers patients a small full-featured device and gives physicians greater flexibility in lead placement, which is especially important when navigating difficult anatomy," said Dr. Rosenthal. New Trial Signifies Continued Leadership in Heart Failure Clinical Science In many cases, this inefficient pumping occurs because the four chambers of the heart are not working as a team. "Today''s implant went remarkably well thanks to the handling characteristics of the EASYTRAK 3 and the entire complement of tools that Guidant has pioneered to facilitate a predictable implant." Information included may not apply to all previous versions of the product. Guidant''s EASYTRAK lead design was the first to allow the physician to position the electrode in a coronary vein on the left side of the heart using a convenient over-the-wire technique similar to the system used in angioplasty procedures. Guidant Corporation, part of Boston Scientific  and Abbott Labs, designs and manufactures artificial cardiac pacemakers, implantable cardioverter-defibrillators, stents, and other cardiovascular medical products. About the EASYTRAK 3 Lead The Guidant Institute for Therapy Advancement - Japan is modeled on the successful Guidant Institute for Therapy Advancement - Europe, which facilitates educational courses on cardiac and vascular therapies for approximately 2,000 clinicians each year. All rights reserved. The EASYTRAK lead was approved for use in the United States in May 2002. Preliminary results of the COMPANION trial were presented at the American College of Cardiology 52nd Annual Scientific Session in March 2003. The EASYTRAK lead, in conjunction with leads implanted in the right side of the heart, allows the device to sense and stimulate both the left and right sides of the heart. The availability of dual electrodes and dual steroid collars with the EASYTRAK 3 create bipolar sensing and pacing capabilities. During the trial, the lead will be implanted in conjunction with the CONTAK® RENEWAL(tm) 3 cardiac resynchronization therapy defibrillator (CRT-D). Their company headquarters is located in Indianapolis, Indiana. Guidant sponsored clinical research and development in the area of heart failure continues to advance heart failure therapies and provide answers to critical clinical questions about long-term treatment outcomes for cardiovascular disease. Boston Scientific is dedicated to transforming lives through innovative medical solutions that improve the health of patients around the world. "We are confident that this Institute will fill an important need in Japan to provide cardiac specialists with more access to, and experience with, rapidly changing cardiovascular therapies and techniques." Their main competitors are Medtronic, St. Jude Medical, and Johnson and Johnson. Product Literature varies by geography. Heart failure currently affects nearly five million Americans and is increasing each year in both prevalence and incidence. The scientific integrity of programs at the Institute will be guaranteed by independent course directors, who are widely respected physicians and who have extensive daily clinical practice. ©2019 Boston Scientific Corporation or its affiliates. The company, driven by a strong entrepreneurial culture of 11,000 employees, develops, manufactures and markets a broad array of products and services that enable less invasive care for some of life''s most threatening … If you need further assistance, please contact customer support. The RENEWAL 3 CRT-D builds on the success of the RENEWAL family and offers a wide range of diagnostics and therapies in a new smaller physiologic shape. It is a disease in which the heart weakens and gradually loses the ability to pump blood effectively. For more information visit www.guidant.com. All rights reserved. Guidant Corporation pioneers lifesaving technology, giving an opportunity for better life today to millions of cardiac and vascular patients worldwide. Guidant was the first company to receive approval to market a CRT-D system for the treatment of heart failure in the United States, the first to offer a CRT-D device with independent channels, and the first to offer a fourth-generation CRT-D device. The Institute is part of Guidant''s ongoing commitment to providing physicians with the latest training and technology to advance the treatment of cardiovascular disease. For more information about Guidant''s cardiac resynchronization therapy products for the treatment of heart failure, please visit www.guidant.com/products/crtd_us.shtml.  All rights reserved. At Boston Scientific, we draw strength from the unique talents and abilities inherent in a diverse workforce and we believe that the best and most innovative products come from an inclusive workplace where varied viewpoints are welcomed and encouraged. Review configuration characteristics to ensure appropriate selection. Boston Scientific is dedicated to transforming lives through innovative medical solutions that improve the health of patients around the world.  To search, please start by selecting your country, language, and role. Guidant is advancing clinical science by sponsoring landmark studies such as the Comparison of Medical Therapy, Pacing, and Defibrillation in Chronic Heart Failure (COMPANION) trial. Guidant Corporation pioneers lifesaving technology, giving an opportunity for better life today to millions of cardiac and vascular patients worldwide. The timing, or synchrony, between the chambers is often poor. These independent channels enable independent pacing and sensing in the left and right ventricles, and are intended to assist the physician in tailoring therapy for individual patients. The company, driven by a strong entrepreneurial culture of 11,000 employees, develops, manufactures and markets a broad array of products and services that enable less invasive care for some of life''s most threatening … Cardiac Resynchronization Therapy (CRT) Devices, Medical Device ID Cards - Pacemaker, ICD, & CRT devices, Remote Patient Monitoring and Diagnostic Monitoring - Boston Scientific. "Our pioneering work in device-based solutions for heart failure spans over 13 years. The EASYTRAK 3 lead is Guidant''s newest heart failure therapy lead using its proprietary over-the-wire design. ";s:7:"keyword";s:37:"guidant corporation boston scientific";s:5:"links";s:593:"<a href="http://newdestinychurchpc.com/blog/article.php?tag=laura-robson-instagram-6bb478">Laura Robson Instagram</a>,
<a href="http://newdestinychurchpc.com/blog/article.php?tag=elon-musk-twitter-6bb478">Elon Musk Twitter</a>,
<a href="http://newdestinychurchpc.com/blog/article.php?tag=james-legros-zodiac-6bb478">James Legros Zodiac</a>,
<a href="http://newdestinychurchpc.com/blog/article.php?tag=characteristics-of-venture-capital-ppt-6bb478">Characteristics Of Venture Capital Ppt</a>,
<a href="http://newdestinychurchpc.com/blog/article.php?tag=iknow-english-6bb478">Iknow English</a>,
";s:7:"expired";i:-1;}